Social Anxiety Disorder
Cluster Number:
Wiki Number: PW208
Diagnosis: Social Anxiety Disorder
US Patients: 66% were co-morbid with another anxiety disorder, most commonly depression(1.49-3.5X)
World Patients:
Sex Ratio:
Age Onset:
Brain Area: amygdala becomes hyperactive, dopamine lower in the striatum, serotonin lower, anterior cingulate cortex-social pain!
Symptoms: fearing negative evaluation from others producing fear, anxiety and distress with impaired ability in social situations
Progression: stammering, rapid speehc, panic attacks, low self-esteem, sleep deprivation. Avoidance of social situations
Causes: 2/3 genetics or observational learning from a relative, socially isolated, insecurem shame, alcohol, core beliefs about self
Medications: SSRIs. Antidepressants, beta-blockers,
Therapies: CBT, Wolpe’s systematic-desensitization
4 CURRENT ARTICLES
FROM PUBMED
The world-wide medical research
reports chosen for each diagnosis
Clicking each title opens the
PubMed article’s summary-abstract.
- Apparent autistic traits in transgender people: a prospective study of the impact of gender-affirming hormonal treatmentby F Mazzoli on July 2, 2022
CONCLUSIONS: The autistic traits in our sample may represent an epiphenomenon of GD rather than being part of an Autism Spectrum Disorder (ASD) condition, since they significantly decreased after 12 months of GAHT.
- Serum metabolomics study of anxiety disorder patients based on LC-MSby Hongqian Kui on July 2, 2022
In the current environment of increasing social pressure, anxiety disorder has become a kind of health problem that needs to be solved urgently. However, the pathological mechanism of anxiety is still unclear, the classification of clinical diagnosis and symptoms is complex, and there is still a lack of biomarkers that can be identified and judged METHODS: This study used LC-MS and non-targeted metabolomics to analyze the clinically collected plasma of 18 samples from anxiety disorder patients...
- Impact of COVID-19 among people who use drugs: A qualitative study with harm reduction workers and people who use drugsby Fiona N Conway on July 2, 2022
CONCLUSIONS: Our study highlighted critical systemic failures that contributed to the rise in overdose deaths during the COVID-19 pandemic. Addressing these challenges through policy reform and improved funding models will ensure the sustainability of harm reduction services and increase access to substance use treatment among highly vulnerable people who use drugs.
- Can Pediatric Primary Care Practices Afford Integrated Behavioral Health? A Comparison of 5 Pediatric Practicesby A D Cummings on July 1, 2022
Licensed behavioral health providers (LBHPs) were integrated into 5 pediatric primary care practices in southeast and east Texas from October 2018 through March 2020. LBHPs Licensed behavioral health providers across the sites were 3 licensed clinical social workers (LCSW), 1 psychologist, and 1 nurse practitioner (NP). Practices provided data for 6 to 15 months. Overall, 2769 units of behavioral health services were provided to 746 children over 2243 hours. Across 4 sites, 44.3% of behavioral...